comprehensive -WSS

comprehensive

author：Wikipedia 2025-10-02 19:15:33 - browse：9948

Fran van Delft for Galapagos

Seeking to differentiate itself from other makers of CAR-T cancer therapies, Galapagos NV on Wednesday announced it had struck a deal with Blood Centers of America to open up dozens of manufacturing sites for its cell-based medicines around the U.S.

Galapagos said it will rely on the partnership, the financial terms of which were not disclosed, as it moves its CAR-Ts for different cancers into pivotal studies and could also help launch those medicines should they win approval. The Belgian company framed the collaboration as one that could help overcome the limitations that have held back access to existing CAR-T therapies from other companies.

CAR-Ts have proven to be potent treatments for certain cancers, but they are complicated medicines to make. Immune cells have to be removed from a patient, shipped to specialty sites, where they’re engineered with cancer-killing abilities, and then returned to the hospital for infusion back into patients. The process, which can take weeks if not months, has put a crunch on the number of patients companies and hospitals are able to treat.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Dementia risk linked to living in disadvantaged areas: Study

WSS

Dementia risk linked to living in disadvantaged areas: Study

An inside look at PIPEs, biotech's buzzy new financing tool

RaDonda Vaught to speak at CommonSpirit event on patient safety

International team creates first chimeric human

International team creates first chimeric human

Congress gives doctors Medicare pay bump

knowledge

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Drug repurposing or repositioning? The language matters

International team creates first chimeric human

BioMarin wins approval for gene therapy to treat hemophilia A

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Flu vaccine offering decent levels of protection this winter, new data show

Drug repurposing or repositioning? The language matters

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

Hepatitis C has a cure — but many Americans still lack access to it

How a Boston hospital is priming medical residents to use GPT

knowledge

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

Thousands of UK hospital doctors walk out in the latest pay dispute, crippling health services

'Golden Bachelor' Gerry Turner reveals what he wants in a partner and more

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

Flu vaccine offering decent levels of protection this winter, new data show

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

explore

hotspot

knowledge

hotspot